Evidence map›Paper›PMID 40143909›Full record

ArticleJHLT open2024

Iatrogenic esophageal dysmotility as a barrier to transplantation in pulmonary arterial hypertension.

Michael S Miller, Shelsey W Johnson, Alexander R Opotowsky, Michael J Landzberg, Nirmal S Sharma, Hilary J Goldberg, Alexandra K Wong, Alison S Witkin, Josanna Rodriguez-Lopez, Ronald H Goldstein and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JHLT open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Michael S MillerDepartment of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Shelsey W JohnsonDivision of Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Alexander R OpotowskyDepartment of Pediatrics, University of Cincinnati School of Medicine, Cincinnati, Ohio.
Michael J LandzbergDivision of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Nirmal S SharmaDivision of Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Hilary J GoldbergDivision of Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Alexandra K WongDepartment of Medicine, Division of Pulmonary and Critical Care Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
Alison S WitkinDepartment of Medicine, Division of Pulmonary and Critical Care Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
Josanna Rodriguez-LopezDepartment of Medicine, Division of Pulmonary and Critical Care Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
Ronald H GoldsteinDepartment of Pulmonary, Allergy, Sleep, and Critical Care Medicine, Veterans Affairs Boston Healthcare System, Boston, Massachusetts.
Bradley A MaronDepartment of Medicine, University of Maryland School of Medicine, Baltimore, MD and the University of Maryland-Institute for Health Computing, Bethesda, Maryland.
Bradley M WertheimDivision of Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.

Funding

Ubiquitination and Endothelial Fibrosis in Early Pulmonary Arterial HypertensionK08HL151976 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI WERTHEIM, BRADLEY · 2020 to 2024
$844k
NHLBI NIH HHS K08 HL151976
6 · The paper itself

Abstract

Esophageal dysmotility is identified as a contraindication to lung transplantation at some centers due to increased risks of acute rejection, pulmonary infection, and chronic lung allograft dysfunction. Phosphodiesterase-type 5 inhibitors (PDE5i) are a cornerstone pharmacotherapy for pulmonary arterial hypertension (PAH) and are known to exert off-target effects that may impact lung transplant candidacy, including impaired esophageal contractility and decreased lower esophageal sphincter tone. We report 2 patients with PAH who were initially declined listing for lung transplantation due to iatrogenic esophageal dysmotility induced by PDE5is. Upon discontinuation of PDE5i therapy, these patients experienced significant improvement in esophageal motility within 14 days and met the criteria for transplant listing at their centers. Recognizing and mitigating the off-target effects of PDE5i medications is critical for maximizing access to transplant for patients with PAH.

Indexed as

esophageal dysmotilitylung transplantationphosphodiesterase-type 5 inhibitorpulmonary arterial hypertension

Identifiers

PMID40143909
PMCPMC11935376

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.